Nora Pöntynen is the Global Capability Owner for Early Access Treatments at Boehringer Ingelheim, a role in which she leads strategic initiatives to enable timely access to innovative therapies for patients worldwide. She joined Boehringer Ingelheim in 2018, bringing with her a wealth of experience across medical affairs and clinical research. Prior to this, Nora held various scientific and medical roles at leading biopharmaceutical companies including Celgene and Eli Lilly and Company. Her responsibilities spanned clinical research, regional medical liaison work, global scientific relations, and medical advisory functions, giving her a comprehensive understanding of the drug development lifecycle and patient access strategies. Nora holds a PhD in Immunology from the University of Helsinki and a Master’s degree in Cellular Biology from Åbo Akademi University.

Boehringer Ingelheim is a family-owned company that has been transforming lives in healthcare since 1885. Its approximately 54,500 employees in 130 markets create value through innovation by infusing long-term, sustainable thinking into our Human Pharma and Animal Health units. The company acknowledges the deep and complex ways the lives of humans and animals are interconnected, works on breakthrough therapies, committed to groundbreaking pharmaceutical innovation across our three business units Human Pharma, Animal Health and Biopharmaceutical Contract Manufacturing, co-creating solutions that help millions of people worldwide live longer, healthier lives.